The effect of delayed time to treatment on survival in women with locally advanced cervical cancer

Robinson, William R.; Shamsnia, Lily; Regn, R.; Pascal, M.

doi:10.1016/j.ygyno.2015.07.091

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Outro estudo de fase II, de braço único, mostrou resultados semelhantes com um esquema neoadjuvante de carboplatina e paclitaxel semanal, seguido de QRT61 .A realização de QTN, para o tratamento do CCLA, pode ser uma estratégia importante em países em desenvolvimento como o Brasil, onde a incidência do CCLA é alta e o número de equipamentos de radioterapia é insuficiente62 . Esta insuficiência pode levar a atrasos no início do tratamento radioterápico, o que se torna um importante fator de mau prognóstico63 . Caso fosse comprovado o benefício da quimioterapia sistêmica neoadjuvante, a doença poderia ser tratada de maneira precoce e os sintomas, como dor pélvica de difícil controle, sangramento vaginal com necessidade de transfusões frequentes e quadros de insuficiência renal pós-renal, poderiam ser evitados ou minimizados.…”

unclassified

Estudo de fase II, prospectivo, randomizado, não comparativo, de tratamento com quimioterapia de indução com cisplatina e gencitabina seguida de quimiorradiação ou quimiorradiação definitiva em carcinomas invasivos da cérvice uterina localmente avançados

Costa¹

View full text Add to dashboard Cite

show abstract

unclassified

Estudo de fase II, prospectivo, randomizado, não comparativo, de tratamento com quimioterapia de indução com cisplatina e gencitabina seguida de quimiorradiação ou quimiorradiação definitiva em carcinomas invasivos da cérvice uterina localmente avançados

Costa¹

View full text Add to dashboard Cite

show abstract

Benchmarking of the Cervical Cancer Care Cascade and Survival Outcomes After Radiation Treatment in a Low- and Middle-Income Country Setting

Grover,

MacDuffie,

Nsingo

et al. 2023

JCO Global Oncology

View full text Add to dashboard Cite

show abstract

Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial

Costa

Bonadio

Gabrielli

et al. 2019

JCO

View full text Add to dashboard Cite

PURPOSE Although chemoradiation therapy (CRT) with cisplatin remains the standard treatment of patients with locally advanced cervical cancer (LACC), 40% of patients present with disease recurrence. Additional treatment strategies are required to improve outcomes. We conducted a trial to evaluate the efficacy and safety of neoadjuvant chemotherapy (NAC) with cisplatin and gemcitabine followed by CRT. METHODS In this phase II trial, patients with LACC (International Federation of Gynecology and Obstetrics stage IIB to IVA or with positive lymph nodes) were randomly assigned to three cycles of NAC with cisplatin and gemcitabine followed by standard CRT with weekly cisplatin plus pelvic radiotherapy or to standard CRT alone. The primary end point was 3-year progression-free survival (PFS). Secondary end points were response rate, 3-year locoregional control, 3-year overall survival (OS), safety, and quality of life. RESULTS From 107 patients enrolled in the trial, 55 were randomly assigned to the NAC arm and 52 to the CRT-alone arm. The majority of patients had squamous cell carcinoma (87.8%). After a median follow-up of 31.7 months, NAC was associated with an inferior PFS, with 3-year PFS rates of 40.9% v 60.4% in the CRT arm (hazard ratio, 1.84; 95% CI, 1.04 to 3.26; P = .033). NAC also was associated with a lower OS (3-year OS rate, 60.7% v 86.8%; hazard ratio, 2.79; 95% CI, 1.29 to 6.01; P = .006). After treatment completion, complete response rates were 56.3% in the NAC arm and 80.3% in the CRT arm ( P = .008). Toxicities were similar in both arms, with the exception of hypomagnesemia and neuropathy being more common with NAC. CONCLUSION This study shows that the addition of NAC consisting of cisplatin and gemcitabine to standard CRT is not superior and is possibly inferior to CRT alone for the treatment of LACC.

show abstract

The effect of delayed time to treatment on survival in women with locally advanced cervical cancer

Cited by 3 publications

References 0 publications

Estudo de fase II, prospectivo, randomizado, não comparativo, de tratamento com quimioterapia de indução com cisplatina e gencitabina seguida de quimiorradiação ou quimiorradiação definitiva em carcinomas invasivos da cérvice uterina localmente avançados

Estudo de fase II, prospectivo, randomizado, não comparativo, de tratamento com quimioterapia de indução com cisplatina e gencitabina seguida de quimiorradiação ou quimiorradiação definitiva em carcinomas invasivos da cérvice uterina localmente avançados

Benchmarking of the Cervical Cancer Care Cascade and Survival Outcomes After Radiation Treatment in a Low- and Middle-Income Country Setting

Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial

Contact Info

Product

Resources

About